Who Johnson & Johnson buys from and sells to
Sells prescription drugs (Darzalex, Tremfya, Carvykti) and medical devices to wholesalers and hospitals.
Buys from 3
Sells to 4
- McKessonMCKdrug and device wholesale in the US
- CencoraCORdrug wholesale in the US
- Cardinal HealthCAHdrug and device wholesale in the US
- Hospitals and health systemssurgical, orthopaedic and cardiovascular devices
Where the chain could break
- Three wholesalers took 21.8%, 15.5% and 11.1% of 2025 gross revenue
- Darzalex is 15% of revenue and rests on a Genmab licence
- Stelara biosimilars are eroding a former top-selling drug
Competes with
- AbbVieABBVSkyrizi and Rinvoq against Tremfya and Stelara
- AmgenAMGNWezlana, a Stelara biosimilar
- MedtronicMDTsurgical and cardiovascular devices
- StrykerSYKorthopaedic implants, a unit J&J plans to separate
Mapped by hand from filings and company reporting, as of October 2026. It shows the relationships that matter most, not every contract: most are never disclosed, and agreements change.